CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionOperating margin is 66.4%, higher than 95% of its Biotechnology peers (median -38%)
- FinancialsAltman Z-Score -1.36: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
489.72MUSDvs all stocks (USD)
Trailing P/E
29.19xvs Biotechnology peers
Revenue (TTM)
316.70MUSDvs all stocks (USD)
Profit Margin
2.94%vs Biotechnology peers
Beta
1.76xvs all stocks
52-Week Change
-11.02%vs all stocks
Market Capitalization
489.72MUSDvs all stocks (USD)
Enterprise Value
-63.62MUSDvs all stocks (USD)
Trailing P/E
29.19xvs Biotechnology peers
Forward P/E
-2.35xvs Biotechnology peers
PEG Ratio
-0.0711xvs Biotechnology peers
Price to Sales (TTM)
1.57xvs Biotechnology peers
Price to Book (MRQ)
0.8816xvs Biotechnology peers
Enterprise to Revenue
-0.2010xvs Biotechnology peers
Enterprise to EBITDA
6.43xvs Biotechnology peers
Profit Margin
2.94%vs Biotechnology peers
Operating Margin
66.36%vs Biotechnology peers
Return on Assets (TTM)
-1.01%vs Biotechnology peers
Return on Equity (TTM)
1.59%vs Biotechnology peers
Revenue (TTM)
316.70MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.75USDUpdated Sep 26, 2026Quarterly Revenue Growth
1014.70%vs Biotechnology peers
Gross Profit (TTM)
307.70MUSDvs all stocks (USD)
EBITDA (TTM)
-9.90MUSDvs all stocks (USD)
Net Income (TTM)
9.30MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1014.73%vs Biotechnology peers
Operating Cash Flow (TTM)
-207.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-94.50MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
262.60MUSDFY2025 · Dec 31, 2025Operating Income
-118.50MUSDvs all stocks (USD)
Pre-tax Income
-80.50MUSDFY2025 · Dec 31, 2025Income Tax Expense
300.00KUSDFY2025 · Dec 31, 2025Net Income
-80.80MUSDFY2025 · Dec 31, 2025EBIT
-118.50MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-113.30MUSDFY2025 · Dec 31, 2025Research & Development
285.20MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
95.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
38.40MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-80.80MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-279.10MUSDFY2025 · Dec 31, 2025Free Cash Flow
-281.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
142.90MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-80.80MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.20MUSDFY2025 · Dec 31, 2025Stock-based Compensation
44.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-8.50MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
7.30MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.70MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-244.60MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.90MUSDFY2025 · Dec 31, 2025Purchase of Investments
-354.20MUSDFY2025 · Dec 31, 2025Sale of Investments
763.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
407.60MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-200.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-91.90MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-92.10MUSDFY2025 · Dec 31, 2025Shares Outstanding
65.30MSharesUpdated Sep 26, 2026Float Shares
56.81MSharesUpdated Sep 26, 2026Shares Short
4.99MSharesUpdated Sep 26, 2026Short Ratio
6.75daysvs all stocks
Short % of Shares Outstanding
8.89%vs all stocks
% Held by Insiders
7.80%vs all stocks
% Held by Institutions
83.75%vs all stocks
Total Cash (MRQ)
567.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.69USDUpdated Sep 26, 2026Total Debt (MRQ)
8.00MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0142xvs Biotechnology peers
Current Ratio (MRQ)
7.91xvs Biotechnology peers
Book Value per Share (MRQ)
8.61USDUpdated Sep 26, 2026Total Assets
717.90MUSDvs all stocks (USD)
Total Current Assets
700.70MUSDFY2025 · Dec 31, 2025Total Liabilities
284.10MUSDFY2025 · Dec 31, 2025Total Non-current Assets
17.20MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
141.60MUSDFY2025 · Dec 31, 2025Total Current Liabilities
142.50MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
142.90MUSDFY2025 · Dec 31, 2025Other Short-term Investments
542.50MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.00MUSDFY2025 · Dec 31, 2025Accounts Payable
24.40MUSDFY2025 · Dec 31, 2025Short-term Debt
1.70MUSDFY2025 · Dec 31, 2025Deferred Revenue
71.30MUSDFY2025 · Dec 31, 2025Long-term Debt
7.20MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
100.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-1.61BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
433.80MUSDvs all stocks (USD)
Treasury Stock
91.90MUSDFY2025 · Dec 31, 202552-Week Low
6.97USDUpdated Sep 26, 202652-Week High
14.51USDUpdated Sep 26, 202652-Week Change
-11.02%vs all stocks
Beta
1.76xvs all stocks
50-Day MA
8.68USDUpdated Sep 26, 2026200-Day MA
10.27USDUpdated Sep 26, 2026Avg 10-Day Volume
1.11MSharesUpdated Sep 26, 2026Avg 30-Day Volume
768.15KSharesUpdated Sep 26, 2026Diluted EPS (TTM)
0.2600USDUpdated Sep 26, 2026Other Income / Expense
-400.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Is this company growing?
Diagnostic
Total Revenue Growth With Buyback Amplification And Heavy SGA
Revenue is growing and buybacks shrink the share count, so per-share growth runs faster.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 66.4%, higher than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: 0.66Industry median: -0.38Industry P95: 0.40Peers compared: 260
Price-to-book is 0.88×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.88Industry median: 2.86Industry P5: 0.98Peers compared: 260
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 9,300,000Operating Cash Flow (USD, TTM): -207,000,000
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 7.91Altman Z-Score: -1.36
Financial Health
Altman Z-Score -1.36: distress zoneCritical
Altman Z-Score: -1.36
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shandong Sinobioway Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanhua Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Onconic Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chison Medical Technologies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huaren Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangsu Tongli Risheng Machinery Co., Ltd.
1 interpretationHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Guararapes Confecções S.A.
1 interpretationHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Hiecise Precision Equipment Co., Ltd.
1 interpretationHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration